rs397517689
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_001267550.2(TTN):c.71602C>T(p.Arg23868Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000411 in 1,461,370 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001267550.2 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TTN | NM_001267550.2 | c.71602C>T | p.Arg23868Ter | stop_gained | 326/363 | ENST00000589042.5 | NP_001254479.2 | |
TTN-AS1 | NR_038272.1 | n.2044-8042G>A | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TTN | ENST00000589042.5 | c.71602C>T | p.Arg23868Ter | stop_gained | 326/363 | 5 | NM_001267550.2 | ENSP00000467141 | P1 | |
TTN-AS1 | ENST00000659121.1 | n.417-23066G>A | intron_variant, non_coding_transcript_variant |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000403 AC: 1AN: 248418Hom.: 0 AF XY: 0.00000742 AC XY: 1AN XY: 134722
GnomAD4 exome AF: 0.00000411 AC: 6AN: 1461370Hom.: 0 Cov.: 38 AF XY: 0.00000413 AC XY: 3AN XY: 726978
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:4
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Oct 01, 2020 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 23, 2021 | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Located in the A-band region of titin, where the majority of truncating pathogenic variants associated with DCM have been reported (Herman et al., 2012); This variant is associated with the following publications: (PMID: 28798025, 22335739, 24503780, 28416588, 23975875, 25589632, 26735901, 29447731, 31514951, 33874732) - |
Dilated cardiomyopathy 1G Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Feb 23, 2023 | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: <0.001%). This variant was predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported at least twice as pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000047301 / PMID: 26735901). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, no assertion criteria provided | research | deCODE genetics, Amgen | Jul 21, 2023 | The variant NM_001267550.2:c.71602C>T (chr2:178574530) in TTN was detected in 3 heterozygotes out of 58K WGS Icelanders (MAF= 0,003%). This variant has been reported in ClinVar previously as pathogenic/likely pathogenic. Based on ACMG criteria (PVS1, PM2, PP5) this variant classifies as pathogenic. - |
Likely pathogenic, no assertion criteria provided | clinical testing | Cardiogenetics and Myogenetics Molecular and Cellular Functional Unit, Aphp Sorbonne University-Hopital Pitie Salpetriere | Jan 06, 2024 | - - |
Primary dilated cardiomyopathy Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jul 16, 2019 | The p.Arg21300X variant in TTN has been identified by our laboratory in 2 adults with DCM. In one family, it segregated with disease in 7 affected relatives (including 3 obligate carriers). This variant has also been identified in 0.001% (1/112282) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org) and has been reported in ClinVar (Variation ID: 47301). This nonsense variant leads to a premature termination codon at position 21300, which is predicted to lead to a truncated or absent protein. Nonsense and other truncating variants in TTN are strongly associated with DCM, particularly if they are located in the exons encoding for the A-band region of the protein (Herman 2012, Pugh 2014), where this variant is located. In summary, this variant meets criteria to be classified as pathogenic for DCM in an autosomal dominant manner based on segregation studies and the predicted effect of this variant on the protein. ACMG/AMP Criteria applied: PVS1; PP1_Strong; PM2. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Jul 01, 2015 | - - |
TTN-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 17, 2024 | The TTN c.71602C>T variant is predicted to result in premature protein termination (p.Arg23868*). This variant has been reported in numerous individuals with cardiomyopathies (Supp. Table 2, Jansen et al. 2019. PubMed ID: 31112426; Table S2, Goli. 2021. PubMed ID: 33874732; Table IV, Bourfiss. 2022. PubMed ID: 36264615; Table S1, Ware. 2016. PubMed ID: 26735901). This variant is located in the A-band region of the protein in which truncating TTN variants have been found more frequently in dilated cardiomyopathy patients than in controls (Herman et al. 2012. PubMed ID: 22335739). RNAseq studies from heart tissue indicate this exon is commonly included in TTN mRNA transcripts (PSI of 95-100%) (Roberts et al. 2015. PMID: 25589632; https://cardiodb.org/titin/titin_transcripts.php). This variant is reported in 0.00089% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Nonsense variants in TTN are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Autosomal recessive limb-girdle muscular dystrophy type 2J;C1858763:Dilated cardiomyopathy 1G Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 30, 2023 | This sequence change creates a premature translational stop signal (p.Arg23868*) in the TTN gene. While this is not anticipated to result in nonsense mediated decay, it is expected to create a truncated TTN protein. This variant is present in population databases (rs397517689, gnomAD 0.0009%). This premature translational stop signal has been observed in individuals with dilated cardiomyopathy and/or peripartum cardiomyopathy (PMID: 26735901, 28416588; Invitae). This variant is also known as chr2:179439257G>A and c.44407C>T (p.Arg14803*). ClinVar contains an entry for this variant (Variation ID: 47301). This variant is located in the A band of TTN (PMID: 25589632). Truncating variants in this region are significantly overrepresented in patients affected with dilated cardiomyopathy (PMID: 25589632). Truncating variants in this region have also been reported in individuals affected with autosomal recessive centronuclear myopathy (PMID: 23975875). For these reasons, this variant has been classified as Pathogenic. - |
Cardiomyopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Apr 29, 2022 | - - |
Dilated cardiomyopathy 1G;C1861065:Hypertrophic cardiomyopathy 9 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | New York Genome Center | Aug 03, 2023 | The c.71602C>T p.(Arg23868Ter) stop-gain variant identified in the TTN gene has been previously reported in individuals with titinopathies [PMID: 31514951, 26735901, 28416588, 29447731], and has been deposited in ClinVar as Pathogenic/Likely Pathogenic by multiple laboratories [ClinVar ID: 47301]. The c.71602C>T variant is present as a single heterozygous allele in population databases (gnomAD v2.1.1 and v3.1.2, TOPMed Freeze 8), suggesting it is not a common benign variant in the populations represented in those databases. The c.71602C>T variant is located in exon 326 (A band) of this 363-exon gene, is predicted to incorporate a premature translation termination codon [p.(Arg23868Ter)], and is expected to result in loss-of-function through protein truncation or nonsense mediated mRNA decay. Truncating variants in this region are significantly overrepresented in patients affected with dilated cardiomyopathy [PMID: 25589632]. Based on available evidence, this c.71602C>T p.(Arg23868Ter) variant identified in TTN is classified as Pathogenic. - |
Autosomal recessive limb-girdle muscular dystrophy type 2J;C1838244:Tibial muscular dystrophy;C1858763:Dilated cardiomyopathy 1G;C1861065:Hypertrophic cardiomyopathy 9;C1863599:Myopathy, myofibrillar, 9, with early respiratory failure;C2673677:Early-onset myopathy with fatal cardiomyopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Nov 06, 2021 | - - |
Primary familial dilated cardiomyopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute | Feb 16, 2017 | - - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 29, 2022 | The p.R14803* pathogenic mutation (also known as c.44407C>T), located in coding exon 153 of the TTN gene, results from a C to T substitution at nucleotide position 44407. This changes the amino acid from an arginine to a stop codon within coding exon 153. This exon is located in the A-band region of the N2-B isoform of the titin protein and is constitutively expressed in TTN transcripts (percent spliced in or PSI 100%). This variant (also referred to as p.R23868* and p.R14995*) has been identified in individuals from peripartum cardiomyopathy, dilated cardiomyopathy, and noncompaction cardiomyopathy cohorts (Ware JS et al. N. Engl. J. Med., 2016 Jan;374:233-41; Dal Ferro M et al. Heart, 2017 11;103:1704-1710; Miszalski-Jamka K et al. Circ Cardiovasc Genet. 2017 Aug;10(4); van Waning JI et al. J Am Coll Cardiol. 2018 Feb;71(7):711-722; Jansen M et al. Circ Genom Precis Med. 2019 May;12(5):e002436). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. While truncating variants in TTN are present in 1-3% of the general population, truncating variants in the A-band are the most common cause of dilated cardiomyopathy (DCM) (Herman DS et al. N. Engl. J. Med., 2012 Feb;366:619-28; Roberts AM et al. Sci Transl Med, 2015 Jan;7:270ra6). TTN truncating variants encoded in constitutive exons (PSI >90%) have been found to be significantly associated with DCM regardless of their position in titin (Schafer S et al. Nat. Genet., 2017 01;49:46-53). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at